Announcing a Proposed Class Action Settlement Involving All Persons that Purchased Shares of ARIAD Pharma Publicly Traded Common Stock During Settlement Class Period

 

 
[12-February-2018]
 
 

BOSTON, Feb. 12, 2018 /PRNewswire/ --

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

    IN RE ARIAD PHARMACEUTICALS, ) No. 1:13-cv-12544
                                   (WGY)
    INC. SECURITIES LITIGATION
                                 )

TO: All persons and entities that purchased, or otherwise acquired, shares of ARIAD Pharmaceuticals, Inc. publicly traded common stock during the period from December 11, 2012 through December 14, 2012, inclusive, and were damaged thereby (the "Settlement Class").

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the Court, that the above-captioned action has been certified as a class action for purposes of a proposed settlement in the amount of $3,500,000 in cash, that if approved, will resolve the action in its entirety.

A hearing will be held before the Honorable William G. Young in the John Joseph Moakley United States Courthouse, 1 Courthouse Way, 5th Floor, Courtroom 18, Boston, Massachusetts 02210, at 2:00 p.m., on May 10, 2018 to determine whether the proposed settlement should be approved by the Court as fair, reasonable, and adequate, and to consider the application of Plaintiffs' Co-Lead Counsel for attorneys' fees and reimbursement of expenses. The Court may change the date of the hearing without providing another notice. You do not need to attend the hearing to receive a distribution from the Net Settlement Fund.

IF YOU ARE A MEMBER OF THE SETTLEMENT CLASS DESCRIBED ABOVE, YOUR RIGHTS WILL BE AFFECTED AND YOU MAY BE ENTITLED TO SHARE IN THE SETTLEMENT FUND. If you have not yet received the full printed Notice of Pendency of Class Action and Proposed Settlement, Motion for Attorneys' Fees and Settlement Fairness Hearing (the "Notice") and a Proof of Claim form (the "Claim Form"), you may obtain copies of these documents by contacting the Claims Administrator:

In re ARIAD Pharmaceuticals, Inc. Securities Litigation
c/o Epiq Systems, Inc.
Claims Administrator
P.O. Box 4230
Portland, OR 97208-4230
(888) 524-4593
www.AriadSecuritiesLitigation.com

Inquiries, other than requests for the Notice and Claim Form, may be made to Plaintiffs' Co-Lead Counsel:

John C. Browne
BERNSTEIN LITOWITZ
BERGER & GROSSMANN LLP
1251 Avenue of the Americas
New York, NY 10020
Tel: (800) 380-8496
Fax: (212) 554-1444
johnb@blbglaw.com

Jonathan Gardner
LABATON SUCHAROW LLP
140 Broadway
New York, NY 10005
Tel: (888) 219-6877
Fax: (212) 818-0477
settlementquestions@labaton.com

Sanford P. Dumain
MILBERG TADLER PHILLIPS GROSSMAN LLP
One Pennsylvania Plaza, Suite 1920
New York, NY 10119
Tel: (800) 320-5081
Fax: (212) 868-1229
sdumain@milberg.com

To participate in the Settlement, you must submit a Claim Form online using the settlement website www.AriadSecuritiesLitigation.com or by mail, such that it is postmarked or received no later than April 26, 2018. If you are a Settlement Class Member and do not exclude yourself from the Settlement Class, you will be bound by the Order and Final Judgment of the Court. To exclude yourself from the Settlement Class, you must submit a request for exclusion in accordance with the instructions set forth in the Notice such that it is postmarked no later than April 19, 2018. Any objections to the Settlement must be filed no later than April 19, 2018. If you are a Settlement Class Member and do not submit a proper Claim Form, you will not share in the Settlement but you nevertheless will be bound by the Order and Final Judgment of the Court.

Further information may be obtained by contacting the Claims Administrator. Please do not contact the Court, Defendants, or Defendants' Counsel regarding this notice.

BY ORDER OF THE COURT

URL: www.AriadSecuritiesLitigation.com

 

View original content:http://www.prnewswire.com/news-releases/announcing-a-proposed-class-action-settlement-involving-all-persons-that-purchased-shares-of-ariad-pharmaceuticals-inc-publicly-traded-common-stock-during-settlement-class-period-300596722.html

SOURCE Labaton Sucharow LLP, Bernstein Litowitz Berger & Grossmann LLP, and Milberg Tadler Phillips Grossman LLP

 

Back to news